Propionyl-L-carnitine-d3 (chloride) (Synonyms: C3:0 Carnitine-d3, CAR 3:0-d3, L-Carnitine propionyl ester-d3, Levocarnitine propionate-d3, L-Propionylcarnitine-d3) |
Catalog No.GC47980 |
An internal standard for the quantification of propionyl-L-carnitine
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1334532-19-2
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Propionyl-L-carnitine-d3 is intended for use as an internal standard for the quantification of propionyl-L-carnitine by GC- or LC-MS. Propionyl-L-carnitine is a naturally occurring carnitine derivative formed by carnitine acetyltransferase during β-oxidation of uneven chain fatty acids.1 Propionyl-L-carnitine increases the basal release of prostaglandin E2 and 6-keto Prostaglandin F1α in carrageenan-stimulated isolated rat peritoneal cells contaminated with neutrophils and increases the basal release of thromboxane B2 in non-contaminated cells.1 It reduces the production of reactive oxygen species (ROS) and decreases the expression of NADPH oxidase 2 (NOX2), NOX4, and ICAM-1 in human umbilical vein endothelial cells (HUVECs). It also increases the rate of revascularization and the hind limb vascular area in a rabbit model of hind limb ischemia when administered at a dose of 10 mg per animal.2 Propionyl-L-carnitine reduces mitochondrial dysfunction induced by ischemia, preventing mitochondrial calcium overload, and depletion of ATP tissue stores in a rabbit model of ischemia.3
1.Garrelds, I.M., Elliott, G.R., Pruimboom, W.M., et al.Effects of carnitine and its congeners on eicosanoid discharge from rat cells: Implications for release of TNFαMediators of Inflammation2(7)S57-S62(1993) 2.Stasi, M.A., Scioli, M.G., Arcuri, G., et al.Propionyl-L-carnitine improves postischemic blood flow recovery and arteriogenetic revascularization and reduces endothelial NADPH-oxidase 4-mediated superoxide productionArterioscler. Thromb. Vasc. Biol.30(3)426-435(2010) 3.Ferrari, R., Ceconi, C., Cargnoni, A., et al.The effect of propionyl-L-carnitine on the ischemic and reperfused intact myocardium and on their derived mitochondriaCardiovasc. Drugs Ther.5 (Suppl 1)57-65(1991)
Cas No. | 1334532-19-2 | SDF | |
Synonyms | C3:0 Carnitine-d3, CAR 3:0-d3, L-Carnitine propionyl ester-d3, Levocarnitine propionate-d3, L-Propionylcarnitine-d3 | ||
Canonical SMILES | C[N+](C)(C([2H])([2H])[2H])C[C@@H](CC(O)=O)OC(CC)=O.[Cl-] | ||
Formula | C10H17D3NO4.Cl | M.Wt | 256.7 |
Solubility | DMF: 15 mg/ml,DMSO: 20 mg/ml,Ethanol: 25 mg/ml,PBS (pH 7.2): 10 mg/ml | Storage | Store at -20°C |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
1 mg | 5 mg | 10 mg | |
1 mM | 3.8956 mL | 19.478 mL | 38.956 mL |
5 mM | 0.7791 mL | 3.8956 mL | 7.7912 mL |
10 mM | 0.3896 mL | 1.9478 mL | 3.8956 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Average Rating: 5
(Based on Reviews and 4 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *